| Primary |
| Gestational Trophoblastic Tumour |
20.7% |
| Rhabdomyosarcoma |
12.9% |
| Nephroblastoma |
9.0% |
| Neoplasm Malignant |
7.6% |
| Renal Neoplasm |
6.3% |
| Choriocarcinoma |
5.9% |
| Aesthesioneuroblastoma |
4.9% |
| Fibrosarcoma |
4.1% |
| Sarcoma |
3.9% |
| Product Used For Unknown Indication |
3.7% |
| Ewing's Sarcoma Metastatic |
3.5% |
| Malignant Melanoma |
3.1% |
| Atypical Teratoid/rhabdoid Tumour Of Cns |
2.9% |
| Ewing's Sarcoma |
2.5% |
| Germ Cell Cancer |
2.3% |
| Sarcoma Metastatic |
1.6% |
| Drug Use For Unknown Indication |
1.4% |
| Ovarian Germ Cell Cancer |
1.4% |
| Congenital Fibrosarcoma |
1.2% |
| Malignant Hydatidiform Mole |
1.2% |
|
| Malnutrition |
13.0% |
| Ototoxicity |
12.0% |
| Therapeutic Agent Toxicity |
10.0% |
| Sepsis |
9.0% |
| Venoocclusive Liver Disease |
7.0% |
| Vomiting |
6.0% |
| White Blood Cell Count Decreased |
6.0% |
| Death |
4.0% |
| Neutropenic Sepsis |
4.0% |
| Toxicity To Various Agents |
4.0% |
| Venoocclusive Disease |
4.0% |
| Hypothyroidism |
3.0% |
| Platelet Count Decreased |
3.0% |
| Rhabdomyolysis |
3.0% |
| Bacterial Sepsis |
2.0% |
| Convulsion |
2.0% |
| Drug Toxicity |
2.0% |
| Fasciotomy |
2.0% |
| Haematotoxicity |
2.0% |
| Hypophagia |
2.0% |
|
| Secondary |
| Rhabdomyosarcoma |
22.5% |
| Testicular Mass |
8.1% |
| Benign Hydatidiform Mole |
7.7% |
| Herpes Zoster |
7.2% |
| Product Used For Unknown Indication |
6.2% |
| Chemotherapy |
5.7% |
| Carcinoma In Situ |
4.8% |
| Choriocarcinoma |
4.8% |
| Metastases To Lung |
4.8% |
| Drug Use For Unknown Indication |
3.3% |
| Prophylaxis Of Nausea And Vomiting |
3.3% |
| Bone Sarcoma |
2.9% |
| Insomnia |
2.9% |
| Lung Neoplasm |
2.9% |
| Neoplasm Malignant |
2.9% |
| Pyrexia |
2.9% |
| Nausea |
1.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.9% |
| Vomiting |
1.9% |
| Hypertension |
1.4% |
|
| Vomiting |
12.5% |
| Embolism Arterial |
10.0% |
| Peripheral Embolism |
10.0% |
| Treatment Related Secondary Malignancy |
10.0% |
| Febrile Neutropenia |
7.5% |
| Urine Output Decreased |
7.5% |
| Ejection Fraction Decreased |
5.0% |
| Hepatic Enzyme Increased |
5.0% |
| Stomatitis |
5.0% |
| Acute Myeloid Leukaemia |
2.5% |
| Bone Sarcoma |
2.5% |
| Inappropriate Antidiuretic Hormone Secretion |
2.5% |
| Lung Adenocarcinoma |
2.5% |
| Medication Error |
2.5% |
| Multiple Sclerosis |
2.5% |
| Nephroblastoma |
2.5% |
| Oedema Peripheral |
2.5% |
| Renal Impairment |
2.5% |
| Rhabdomyolysis |
2.5% |
| Stevens-johnson Syndrome |
2.5% |
|
| Concomitant |
| Ewing's Sarcoma |
17.1% |
| Rhabdomyosarcoma |
17.1% |
| Testicular Mass |
17.1% |
| Antiemetic Supportive Care |
14.6% |
| Product Used For Unknown Indication |
7.3% |
| Prophylaxis |
7.3% |
| Testis Cancer |
7.3% |
| Diabetes Mellitus |
2.4% |
| Malignant Fibrous Histiocytoma |
2.4% |
| Prophylaxis Of Nausea And Vomiting |
2.4% |
| Sarcoma |
2.4% |
| Thrombosis Prophylaxis |
2.4% |
|
| Bronchospasm |
11.1% |
| Convulsion |
11.1% |
| Demyelinating Polyneuropathy |
11.1% |
| Infection |
11.1% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
11.1% |
| Pulmonary Fibrosis |
11.1% |
| Rash Pruritic |
11.1% |
| Renal Tubular Disorder |
11.1% |
| Treatment Related Secondary Malignancy |
11.1% |
|
